EGFR and non-small cell lung carcinoma: 33 studied the ddPCR method to dynamically detect EGFR mutations in patients’ plasma. The results demonstrated that T790M ctDNA mutation in plasma was detected in 55 (47%) of the 117 patients. And the overall concordance rate of T790M testing between the paired tumor tissues and plasma was 88.00% (22/25). The sensitivity and specificity of plasma T790M testing by ddPCR assay were 81.25% (13/16) and 100.00% (9/9), respectively. Lee et al. 40 used ddPCR to detect EGFR status in plasma from advanced NSCLC patients.